Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA

Links shared publicly online about this topic.

93
total visits

Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA

AZ-004 (Staccato loxapine) is a new drug in development for the treatment of agitation in patients with schizophrenia or bipolar disorder. AZ-004 information includes news, clinical trial results and side effects.

View full resource at drugs.com

Tags: Bipolar Disorder, Schizophrenia, Psychotic Disorder, Disease and Condition, Drug, News, Nature

Most Recently Shared on August 6, 2011 at 1:15 am By:

Drugs and Devices OW

Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA: MOUNTAIN VIEW, Calif., Aug. 5, 2011 /PRNe... http://bit.ly/oqeC1F #drug

10 months ago...

Retweet

Favorite

Alexza Pharmaceuticals — Investor Relations - RSS Content

phx.corporate-ir.net — “Alexza Pharmaceuticals Welcome” View full resource at phx.corporate-ir.net

Most Recently Shared on August 5, 2011 at 1:15 pm By:

eyeonfda Pharma and Health Lawyer

Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA 4 #Schizophrenia or #Bipolar Disorder - http://ow.ly/5VZLR #FDA

10 months ago...

Retweet

Favorite

Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA

medicalnewstoday.com — “Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA). AZ-004” View full resource at medicalnewstoday.com